Podcast

Homing in on Clinical Advances in Hematologic Malignancies in Chicago

Author(s):

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Rush University Medical Center faculty.

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from Rush University Medical Center shed light on ongoing research that is poised to add new options to the armamentarium in myelofibrosis, highlighted the novel agents that have strengthened treatment options in non-Hodgkin lymphoma, and discussed treatment considerations for patients with Hodgkin lymphoma.

Moreover, faculty shared insights on the novels agents and combinations that have transformed the multiple myeloma treatment paradigm and provided perspective on ongoing research with blinatumomab and CAR T-cell therapy in new settings in acute lymphoblastic leukemia.

Interested in attending an upcoming OncLive® State of the Science Summit in your area? Register today.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.